BLTE
Belite BioยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
BLTE Profile
Belite Bio, Inc
A biopharmaceutical company developing new treatments for currently incurable eye diseases
Pharmaceutical
03/27/2018
04/29/2022
NASDAQ Stock Exchange
25
12-31
Depository Receipts (Ordinary Shares)
12750 High Bluff Drive Suite 475, San Diego, CA 92130
--
Belite Bio, Inc was incorporated in the Cayman Islands on March 27, 2018. The Company is a clinical-stage biopharmaceutical and drug development company focused on novel therapies for currently untreatable eye diseases involving retinal degeneration with significant unmet medical needs, such as (i) atrophic age-related macular degeneration (AMD), commonly known as geographic atrophy (GA), or advanced dry AMD, and (ii) autorecessive chromosomal Stargardt disease type 1, or STGD1, Both diseases can lead to progressive vision loss, leading to permanent blindness. The company's drug pipeline also includes a small molecule oral compound for the treatment of metabolic diseases such as non-alcoholic fatty liver, non-alcoholic steatohepatitis, NASH, type 2 diabetes, T2D and gout.
